Health care; requiring licensed practitioners to offer pharmacogenomic test prior to prescription of psychotropic drugs. Effective date.
Summary
SB29 would create a new requirement in Oklahoma law for licensed practitioners to offer a pharmacogenomic test before prescribing any psychotropic drug. The bill defines this as a test intended to help guide prescribing decisions based on how a patient’s genes may react to certain medications. If the patient agrees, the practitioner must order and administer the test before writing the prescription.
The bill also requires the practitioner to explain, to the best of their knowledge, the test’s efficacy, disclose whether the test is FDA-approved, and obtain the patient’s informed consent before ordering it. If the practitioner knows the cost, they must provide an estimate to the patient. The measure would be codified in Title 63 of the Oklahoma Statutes and take effect November 1, 2025.
Impact
SB29 would add a new statutory section to Oklahoma’s health care laws governing the prescribing of psychotropic medications, creating a pre-prescription testing and disclosure framework for pharmacogenomic testing. It would affect licensed practitioners who prescribe psychiatric medications and patients receiving those medications, while also potentially influencing laboratory testing, informed consent practices, and prescribing workflows in mental health care.
Sentiment
Based on the bill text and available legislative history, the measure appears to have been introduced and referred to the Health and Human Services committee without recorded votes or committee debate in the provided materials. The overall framing is policy-oriented and patient-safety focused, emphasizing genetic testing and informed consent before psychotropic prescribing. Because no transcripts or vote data are available, there is no documented public committee sentiment in the record provided.
Contention
The main potential points of contention are the mandate to offer testing before every psychotropic prescription, the requirement to disclose efficacy and FDA approval status, and the practical burden on practitioners to obtain consent, order testing, and estimate costs. Supporters would likely view the bill as improving personalized medicine and reducing adverse drug reactions, while critics may question the clinical necessity, cost, access, and whether the requirement could delay treatment or create barriers for patients needing timely mental health care.